Literature DB >> 3373114

A simple and accurate microplate assay for the determination of factor XI in plasma.

C F Scott1, R W Colman.   

Abstract

Traditionally, factor XI has been determined in the clinical laboratory by a modified activated partial thromboplastin time assay (aPTT) with factor XI-deficient plasma as the substrate. Coagulant assays, however, have high coefficients of variation. We previously developed a chromogenic assay for factor XI that required equipment not normally found in a clinical laboratory. We now present a modification of that assay, which is performed in 96-well microplates and can be done in any clinical laboratory or physician's office. Plasma is subjected to a brief acidification to inactivate most of the plasma protease inhibitors. Soybean trypsin inhibitor is included to stabilize the factor XIa that is generated. Kaolin is used as the contact activating surface, and the chromogenic substrate, S-2366, is used to measure the factor XIa that is formed. Results of the assay, performed in three groups of subjects, correlate well with results of the coagulant assay as performed in our laboratory and clearly differentiate between total factor XI deficiency and the deficiency of any of the other contact proteins. Unlike coagulation assays, the chromogenic assay is not influenced by the presence of heparin. Furthermore, it is not affected by lupus anticoagulants, which are antibodies directed against acidic phospholipids. Two plasma samples from patients with acquired factor XI inhibitors showed dissociation between coagulant and amidolytic activity, suggesting that the antibodies were not primarily directed toward the active site of factor XIa, which is responsible for its amidolytic activity. In contrast, patients with severe congenital deficiency of factor XI showed no activity by either assay.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3373114

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  7 in total

1.  Kallikrein-kininogen system activation and bradykinin (B2) receptors in indomethacin induced enterocolitis in genetically susceptible Lewis rats.

Authors:  A Stadnicki; R B Sartor; R Janardham; I Stadnicka; A A Adam; C Blais; R W Colman
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

2.  Activation of plasma contact and coagulation systems and neutrophils in the active phase of ulcerative colitis.

Authors:  A Stadnicki; M Gonciarz; T J Niewiarowski; J Hartleb; M Rudnicki; N B Merrell; R A Dela Cadena; R W Colman
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

3.  Elevated tissue factor expression contributes to exacerbated diabetic nephropathy in mice lacking eNOS fed a high fat diet.

Authors:  F Li; C-H Wang; J-G Wang; T Thai; G Boysen; L Xu; A L Turner; A S Wolberg; N Mackman; N Maeda; N Takahashi
Journal:  J Thromb Haemost       Date:  2010-10       Impact factor: 5.824

4.  Selective plasma kallikrein inhibitor attenuates acute intestinal inflammation in Lewis rat.

Authors:  A Stadnicki; R A DeLa Cadena; R B Sartor; D Bender; C A Kettner; H C Rath; A Adam; R W Colman
Journal:  Dig Dis Sci       Date:  1996-05       Impact factor: 3.199

5.  A monoclonal antibody to high-molecular weight kininogen is therapeutic in a rodent model of reactive arthritis.

Authors:  Ricardo G Espinola; Audrey Uknis; Irma M Sainz; Irma Isordia-Salas; Robin Pixley; Raul DeLa Cadena; Walter Long; Alexis Agelan; John Gaughan; Albert Adam; Robert W Colman
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

6.  Activation of the contact system in lethal hypotensive bacteremia in a baboon model.

Authors:  R A Pixley; R A DeLa Cadena; J D Page; N Kaufman; E G Wyshock; R W Colman; A Chang; F B Taylor
Journal:  Am J Pathol       Date:  1992-04       Impact factor: 4.307

7.  The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons.

Authors:  R A Pixley; R De La Cadena; J D Page; N Kaufman; E G Wyshock; A Chang; F B Taylor; R W Colman
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.